SYSTEMATIC REVIEW article
Front. Pharmacol., 04 June 2024
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1378577
RETRACTED: Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis
Junjie Yu 1
Fangang Meng 1
Wenxia Sui 1
Junmin Yu 2*
Jinhai Shen 3*
1. Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
2. Department of Pain Treatment, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
3. Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing, Jiangsu, China
Summary
Citation
Yu J, Meng F, Sui W, Yu J and Shen J (2024) RETRACTED: Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Front. Pharmacol. 15:1378577. doi: 10.3389/fphar.2024.1378577
Received
29 January 2024
Accepted
17 May 2024
Published
04 June 2024
Retracted
07 November 2025
Volume
15 - 2024
Edited by
Rakesh K. Jain, Massachusetts General Hospital and Harvard Medical School, United States
Reviewed by
Benjamin Wolf, Leipzig University, Germany
Nathan Andrew Holland, Texas Tech University Health Sciences Center El Paso, United States
Updates
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.